Liminatus Pharma, Inc. Stock: price and insider trades · United States
Liminatus Pharma, Inc.: what insiders have been doing
This page follows insider dealings at Liminatus Pharma, Inc. as filed with SEC (Form 4). From 8 November 2025 to 8 November 2026, the disclosure feed for Liminatus Pharma, Inc. logged 2 filings by 1 insider.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Over the last twelve months, not one insider purchase of Liminatus Pharma, Inc. stock was filed.
Compared with its exchange (5,813 companies, median 19 filings), a count of 2 filings is below the norm.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Financial data
as of FY 2025FY ended December 2025 · cache
- 3,448,926 sharesCommon Stock, par value $0.0001 per shareSEC:0001104659-26-083588:0
- 4,373,603 sharesCommon Stock, par value $0.0001 per shareSEC:0001104659-26-080806:0
2 of 2 declarations
About Liminatus Pharma, Inc.
Liminatus Pharma, Inc. is a pharmaceutical company focused on developing innovative treatments. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
